XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 9 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating activities    
Net loss $ (4,902) $ (7,327)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Share-based compensation 5,790 5,381
Depreciation and amortization 1,599 1,223
Amortization of intangible assets 4,004 4,340
Amortization of manufacturing profit in acquired inventory associated with acquisitions 696 181
Loss on disposal of property and equipment 0 (10)
Amortization of deferred debt issuance costs 83 77
Fair value remeasurement of earnout consideration (9) (533)
Changes in operating assets and liabilities, net of assets and liabilities acquired:    
Accounts receivable (860) 2,553
Inventories 8,488 (10,637)
Contract manufacturers' receivable 1,457 1,139
Prepaid expenses and other current assets 76 2,260
Lease right-of-use assets 1,455 1,332
Other assets (114) (31)
Accounts payable 1,390 (5,782)
Accrued payroll and related expenses 2,108 (1,918)
Other liabilities (4,913) 6,796
Net cash provided by (used in) operating activities 16,348 (956)
Investing activities    
Purchases of property and equipment (1,325) (2,325)
Cash payment for acquisition, net of cash and cash equivalents acquired 0 (4,650)
Net cash used in investing activities (1,325) (6,975)
Financing activities    
Net proceeds from issuances of common stock 522 752
Tax withholding paid on behalf of employees for restricted shares (881) (674)
Earnout consideration paid for acquisition (1,262) 0
Net proceeds from issuance of debt 0 4,909
Payment of borrowings on term loan (2,075) (1,475)
Net proceeds from borrowing on line of credit 0 2,000
Payment of borrowings on line of credit 0 (2,000)
Payment of lease liabilities (137) (7)
Net cash (used in) provided by financing activities (3,833) 3,505
Increase (decrease) in cash and cash equivalents 11,190 (4,426)
Cash and cash equivalents at beginning of period 13,452 17,221
Cash and cash equivalents at end of period $ 24,642 $ 12,795